937 related articles for article (PubMed ID: 33278108)
1. COVID-19 vaccine development: a pediatric perspective.
Kamidani S; Rostad CA; Anderson EJ
Curr Opin Pediatr; 2021 Feb; 33(1):144-151. PubMed ID: 33278108
[TBL] [Abstract][Full Text] [Related]
2. Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
Anderson EJ; Campbell JD; Creech CB; Frenck R; Kamidani S; Munoz FM; Nachman S; Spearman P
Clin Infect Dis; 2021 Jul; 73(2):336-340. PubMed ID: 32945335
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
[TBL] [Abstract][Full Text] [Related]
4. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
8. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
12. Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
Ali Y; Piche-Renaud PP; Karimi-Shahrbabak E; Farrar DS; Fadaleh SA; Burey S; Morris SK
Vaccine; 2023 May; 41(19):3058-3065. PubMed ID: 37045681
[TBL] [Abstract][Full Text] [Related]
13. The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases.
Stein M; Ashkenazi-Hoffnung L; Greenberg D; Dalal I; Livni G; Chapnick G; Stein-Zamir C; Ashkenazi S; Hecht-Sagie L; Grossman Z
Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062742
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Vaccination in Children: An Open Question.
Campagnani G; Bardanzellu F; Pintus MC; Fanos V; Marcialis MA
Curr Pediatr Rev; 2022; 18(3):226-236. PubMed ID: 34931965
[TBL] [Abstract][Full Text] [Related]
15. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
16. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
17. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
18. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
19. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
Bennet BM; Wolf J; Laureano R; Sellers RS
Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
